Loading data for IRWD — first visit, this takes a few seconds.

알림

Ironwood Pharmaceuticals ... (IRWD)

NasdaqGS: IRWD · 실시간 가격 · USD

4.36

+0.05 (1.16%)

종가 기준: Aug 19, 2026, 8:00 PM

4.38

+0.57%

애프터마켓: 7:09 PM

1.16% (1D)

데이터 없음

매수호가	3.74
시가총액	720.45M
매출 (ttm)	389.32M
순이익 (ttm)	129.87M
베타	0.21
EPS (ttm)	0.79
P/E (ttm)	5.52
선행 P/E	2.96
P/B (ttm)	-3.31
P/S (ttm)	1.85
Earnings Date	Feb 15, 2024

매도호가	4.93
거래량	1,476,014
평균 거래량 (20일)	2,351,993
시가	4.48
전일 종가	4.31
일중 범위	4.30 - 4.49
52주 범위	1.01 - 5.78
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IRWD 소개

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional...

섹터 Healthcare

IPO 일자 Feb 3, 2010

직원 수 100

상장 거래소 NasdaqGS

티커 IRWD

웹사이트 https://ironwoodpharma.com

전체 기업 정보

재무 실적

2025년 Ironwood Pharmaceuticals의 매출은 296.15M로, 전년 351.41M 대비 -15.72% 감소했습니다. 순이익은 24.02M로, 2,629.2% 증가했습니다.

재무제표

어닝 서프라이즈

Ironwood Pharmaceuticals가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $113.04M 예상치 하회 $0, 및 32.62% 전년 대비 성장.

EPS 0.31 예상치 상회 0.03, 및 121.43% 전년 대비 성장.

다음 실적 발표

Ironwood Pharmaceuticals Inc.의 실적 발표 예정일은 Feb 15, 2024, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · Motley Fool

Ironwood (IRWD) Q2 2026 Earnings Call Transcript

LINZESS sales surged 14% as company raised full-year guidance.

1주 전 · Moby

Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Ironwood Pharmaceuticals, Inc.'s Q2 2026 earnings call

1주 전 · Simply Wall St.

Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

Ironwood Pharmaceuticals reported past second-quarter 2026 results showing sales of US$113.04 million versus US$85.24 million a year earlier, with net income rising to US$51.29 million from US$23.6 mi...

1주 전 · GuruFocus.com

Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ...

Ironwood Pharmaceuticals Inc (IRWD) raises full-year 2026 outlook on robust LINZESS performance and promising apraglutide data.

1주 전 · MarketBeat

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its ...

2 페이지 중 1